Molecular Testing: How Can Oncologists Work Better With Pathologists?

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Dr. Aisner discusses some of the key ways oncologists can work better with pathologists at their institutions.

Dara Aisner, MD, PhD, assistant professor at the University of Colorado Anschutz Medical Campus, discusses some of the key things oncologists can do to work better with pathologists at their institutions.

Dr. Aisner also talks about some of the common points of miscommunication between oncologists and pathologists, and some instances in which oncologists might want second opinions on certain pathology tests results.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Related Content
Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC

Roman Fabbricatore
June 9th 2025
Article

Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

Dylann Cohn-Emery
June 6th 2025
Article

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Ashling Wahner
June 5th 2025
Article

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.